Syros Pharmaceuticals Inc (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 0 | 0 | 0 | 387 | 3,762 |
| Gross Profit | N/A | N/A | N/A | 387 | 3,762 |
| Operating Expenses | 26,182 | 27,416 | 30,921 | 27,527 | 38,398 |
| Operating Income | -26,182 | -27,416 | -30,921 | -27,140 | -34,636 |
| Interest Expense | 1,312 | 1,382 | 1,307 | 1,329 | 1,303 |
| Other Income | 21,098 | 5,471 | 28,520 | -35,915 | -4,204 |
| Pre-tax Income | -6,396 | -23,327 | -3,708 | -64,384 | -40,143 |
| Net Income Continuous | -6,396 | -23,327 | -3,708 | -64,384 | -40,143 |
| Net Income | $-6,396 | $-23,327 | $-3,708 | $-64,384 | $-40,143 |
| EPS Basic Total Ops | -0.16 | -0.59 | -0.10 | -2.23 | -1.43 |
| EPS Basic Continuous Ops | -0.16 | -0.59 | -0.10 | -2.22 | -1.43 |
| EPS Diluted Total Ops | -0.16 | -0.59 | -0.10 | -2.23 | -1.43 |
| EPS Diluted Continuous Ops | -0.16 | -0.59 | -0.10 | -2.22 | -1.43 |
| EPS Diluted Before Non-Recurring Items | -0.68 | -0.70 | -0.79 | -1.19 | -1.35 |
| EBITDA(a) | $-25,710 | $-26,964 | $-30,435 | $-26,638 | $-33,881 |